Amina Zoubeidi
From Wikipedia, the free encyclopedia
EducationBsc, Mohammed V University
M.Sc. Université du Québec à Montréal
PhD, Université de Montréal
M.Sc. Université du Québec à Montréal
PhD, Université de Montréal
Amina Zoubeidi | |
|---|---|
| Academic background | |
| Education | Bsc, Mohammed V University M.Sc. Université du Québec à Montréal PhD, Université de Montréal |
| Academic work | |
| Institutions | University of British Columbia Vancouver Coastal Health |
Amina Zoubeidi is a Canadian research scientist and prostate cancer researcher. She's a scientist at the Vancouver Coastal Health Research Institute and a professor in the Department of Urologic Sciences at the University of British Columbia. During her tenure at UBC, Zoubeidi and her research team developed the first drug that targets and blocks BRN2, thus stopping Neuroendocrine prostate cancer (NEPC) tumours and creating a possible treatment for the previously thought incurable disease.[1][2]
Zoubeidi earned her Bachelor of Science degree from the Mohammed V University before moving to Montreal to earn her graduate degrees from the Université du Québec à Montréal and Université de Montréal.[3]